These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36792385)

  • 1. Re: Sensitivity of Multiparametric MRI and Targeted Biopsy for Detection of Adverse Pathologies (Cribriform Gleason Pattern 4 and Intraductal Carcinoma): Correlation of Detected and Missed Prostate Cancer Foci with Whole Mount Histopathology.
    Bernardino R; Fleshner N
    Eur Urol; 2023 Jun; 83(6):583-584. PubMed ID: 36792385
    [No Abstract]   [Full Text] [Related]  

  • 2. Sensitivity of multiparametric MRI and targeted biopsy for detection of adverse pathologies (Cribriform gleason pattern 4 and intraductal carcinoma): Correlation of detected and missed prostate cancer foci with whole mount histopathology.
    Cai Q; Costa DN; Metter CK; Goldberg K; Roehrborn CG; Cadeddu J; Pedrosa I; Meng X; Mostardeiro TR; Shah RB
    Urol Oncol; 2022 Oct; 40(10):452.e1-452.e8. PubMed ID: 36008255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive comparison between mpMRI of the prostate, MR-US fusion biopsy and whole mount histopathology.
    Doblhammer S; Kinger P; Starmuehler M; Muschitz C; Schima W; Susani M; Baierl A; Broessner C
    World J Urol; 2023 Apr; 41(4):1055-1060. PubMed ID: 36840753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy for Quantitative Gleason 4 Grading Prediction in Radical Prostatectomy Specimens: Implications for Active Surveillance Candidate Selection.
    Kachanov M; Budäus L; Beyersdorff D; Karakiewicz PI; Tian Z; Falkenbach F; Tilki D; Maurer T; Sauter G; Graefen M; Leyh-Bannurah SR
    Eur Urol Focus; 2023 Mar; 9(2):303-308. PubMed ID: 36184537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cribriform morphology impairs Gleason 7 prostate cancer lesion detection on multiparametric magnetic resonance imaging.
    Kazan O; Gunduz N; Kir G; Iplikci A; Dogan MB; Cecikoglu GE; Culpan M; Yildirim A
    Prostate; 2023 Mar; 83(4):331-339. PubMed ID: 36477738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer.
    Rayn KN; Bloom JB; Gold SA; Hale GR; Baiocco JA; Mehralivand S; Czarniecki M; Sabarwal VK; Valera V; Wood BJ; Merino MJ; Choyke P; Turkbey B; Pinto PA
    J Urol; 2018 Nov; 200(5):1041-1047. PubMed ID: 29852182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
    Lovegrove CE; Miah S; El-Shater Bosaily A; Bott S; Brown L; Burns-Cox N; Dudderidge T; Freeman A; Henderson A; Hindley R; Kaplan R; Kirkham A; Oldroyd R; Parker C; Persad R; Punwani S; Rosario D; Shergill I; Winkler M; Emberton M; Ahmed HU
    J Urol; 2020 Jan; 203(1):100-107. PubMed ID: 31335254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gleason Score Determination with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Guided Prostate Biopsies--Are We Gaining in Accuracy?
    Lanz C; Cornud F; Beuvon F; Lefèvre A; Legmann P; Zerbib M; Delongchamps NB
    J Urol; 2016 Jan; 195(1):88-93. PubMed ID: 26165586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopsy-Integrated 3D Magnetic Resonance Imaging Modeling of Prostate Cancer and Its Application for Gleason Grade and Tumor Laterality Assessment.
    Kim J; Lim B; Jeong IG; Ro JY; Go H; Cho YM; Park KJ
    Arch Pathol Lab Med; 2023 Feb; 147(2):159-166. PubMed ID: 35512234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.
    Ullrich T; Arsov C; Quentin M; Mones F; Westphalen AC; Mally D; Hiester A; Albers P; Antoch G; Schimmöller L
    Eur Radiol; 2020 Nov; 30(11):6042-6051. PubMed ID: 32591887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
    Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
    Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focused Submission of Tissue for Radical Prostatectomy Following Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion-Targeted Biopsy.
    Fasciano D; Eich ML; Del Carmen Rodriguez Pena M; Rais-Bahrami S; Gordetsky J
    Int J Surg Pathol; 2020 Feb; 28(1):44-50. PubMed ID: 31342804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Percentage Gleason Pattern 4 and PI-RADS Score Predict Upgrading in Biopsy Grade Group 2 Prostate Cancer Patients Without Cribriform Pattern.
    Compérat E; Oszwald A; Wasinger G
    Eur Urol; 2023 May; 83(5):472. PubMed ID: 36707358
    [No Abstract]   [Full Text] [Related]  

  • 15. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
    J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology.
    Le JD; Stephenson S; Brugger M; Lu DY; Lieu P; Sonn GA; Natarajan S; Dorey FJ; Huang J; Margolis DJ; Reiter RE; Marks LS
    J Urol; 2014 Nov; 192(5):1367-73. PubMed ID: 24793118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
    Raman AG; Sarma KV; Raman SS; Priester AM; Mirak SA; Riskin-Jones HH; Dhinagar N; Speier W; Felker E; Sisk AE; Lu D; Kinnaird A; Reiter RE; Marks LS; Arnold CW
    J Urol; 2021 Sep; 206(3):595-603. PubMed ID: 33908801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of clinically significant prostate cancer in biopsy-naïve men: direct comparison of systematic biopsy, multiparametric MRI- and contrast-ultrasound-dispersion imaging-targeted biopsy.
    Mannaerts CK; Engelbrecht MRW; Postema AW; van Kollenburg RAA; Hoeks CMA; Savci-Heijink CD; Van Sloun RJG; Wildeboer RR; De Reijke TM; Mischi M; Wijkstra H
    BJU Int; 2020 Oct; 126(4):481-493. PubMed ID: 32315112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.
    Salmasi A; Said J; Shindel AW; Khoshnoodi P; Felker ER; Sisk AE; Grogan T; McCullough D; Bennett J; Bailey H; Lawrence HJ; Elashoff DA; Marks LS; Raman SS; Febbo PG; Reiter RE
    J Urol; 2018 Sep; 200(3):564-572. PubMed ID: 29524506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of MRI-Targeted in-Bore Prostate Biopsy According to the Gleason Score with Postprostatectomy Histopathologic Control--a Targeted Biopsy-Only Strategy with Limited Number of Cores.
    Garmer M; Busch M; Mateiescu S; Fahlbusch DE; Wagener B; Grönemeyer DH
    Acad Radiol; 2015 Nov; 22(11):1409-18. PubMed ID: 26343218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.